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SUMMARY – Th e aim of this clinical study was to compare low-level laser therapy (LLLT) 
switched on and switched off  in the treatment of burning mouth syndrome (BMS). BMS is a debili-
tating condition for patients and highly demanding for physicians, characterized by burning symp-
toms in the oral cavity. Despite extensive research, so far only cognitive behavioral therapy and clon-
azepam have been proven successful for its treatment in randomized controlled trials. Forty-four pa-
tients with BMS were randomly assigned to the study laser group (LLLT) or the sham laser group. 
LLLT was performed with the GaAlAs laser (830 nm) used in non-contact mode on the site in the 
mouth where burning symptoms were present; study patients received 10 sessions (10 days). Each 
participant fi lled out the visual analog scale (VAS) and oral health impact on the quality of life scale 
(OHIP-CRO 14) before and after either therapy protocol. Th ere were no signifi cant diff erences be-
tween the groups before and after LLLT (switched on and off ) in the quality of life (OHIP CRO 14 
scores) (p>0.05). Th ere was signifi cant decrease in pain symptoms (VAS) in both LLLT switched on 
and LLLT switched off  groups (p<0.05). Both LLLT switched on and switched off  decreased pain 
symptoms (VAS) in patients with BMS; however, neither LLLT switched off  or switched on im-
proved the OHIP-CRO 14 scores.
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Introduction
Burning mouth syndrome (BMS) is a chronic pain 
syndrome characterized by burning symptoms in the 
oral cavity and with clinically healthy appearance of 
the oral mucosa, aff ecting mostly postmenopausal 
women1. Despite many studies, its etiopathogenesis 
has not been elucidated completely, albeit disturbances 
in peripheral and/or central nerve pathways have been 
suggested2. Many of the recommended therapies have 
not been successful except for topical clonazepam and 
cognitive behavioral therapy3. Miziara et al.4 stated 
that so far only topical clonazepam, alpha-lipoic acid 
and cognitive behavioral therapy have proven success-
ful in randomized controlled trials. Furthermore, Cui 
et al.5 searched PubMed, MEDLINE, EMBASE, 
Web of Science (TS) and Cochrane Library and found 
three randomized controlled trials (RCTs) and two 
high-quality case-control studies involving 195 BMS 
patients, which reveal that clonazepam can reduce oral 
pain symptoms in patients with BMS. Klasser et al.6 
also state that there is an urgent need for further inves-
tigations to determine the effi  cacy of diff erent thera-
pies as to determine appropriate therapeutic options 
for BMS suff erers. Beneng and Renton2 concluded 
that, while there is no cure for BMS symptoms, BMS 
patients take various neuropathic pain medication, 
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salivary substitutes and other non-medical interven-
tions that help the patient “get through the day”.
In the published literature on PubMed there are 
only ten studies on the use of low-level laser therapy 
(LLLT) in BMS patients. According to our knowl-
edge, there have been only three studies published so 
far on the placebo eff ect of LLLT (i.e. when LLLT was 
switched off )7-9. Th erefore, the aim of this study was to 
compare switched on and switched off  (sham) LLLT 
in the treatment of BMS.
Materials and Methods
Patient selection
Th is randomized clinical single-blinded study was 
performed in the Osijek Health Centre from Septem-
ber 2015 until June 2016. Th e study was approved by 
the Ethics Committee of the School of Medicine in 
Osijek, Croatia. Standards of the Helsinki Declaration 
were followed10. All selected patients signed an in-
formed consent before undergoing the research proce-
dure, agreeing to their participation in the study.
Th e study sample consisted of 44 participants (one 
male and 43 females; age range 56-83, mean age 67.56 
years), randomly selected from the group of patients 
presenting to dental offi  ce because of the burning mouth 
symptoms. Th e diagnosis of primary BMS was estab-
lished as follows: burning sensation in the otherwise 
clinically normal oral mucosa and absence of local and 
systemic factors that can lead to burning sensation of 
the oral mucosa. Local and systemic factors were elimi-
nated by salivary flow rate test, complete blood count, 
serum iron, vitamin B12, folic acid, thyroid hormones, 
and blood glucose. Th e exclusion criteria were inability 
to comprehend the text of the informed consent form 
and inability to comprehend the questionnaire.
Low-level laser therapy procedure (LLLT)
Prior to and after either therapy, participants fi lled 
out the visual analog scale (VAS) and Oral Health 
 Impact Profi le questionnaire, Croatian version 
(OHIP-CRO 14)11. By simple method of fl ipping the 
coin, participants were allocated in two groups: LLLT 
switched on and LLLT switched off  (control group, 
sham laser group). Th e participants did not know 
which group they were assigned to (single-blinded 
study).
Th e LLLT was performed by the Gallium-Alumi-
num-Arsenide (GaAlAs) laser (BTL, Prague, Czech 
Republic) with wavelength of 830 nm. Laser parameters 
were set at: average power of 100 mW, chopped mode 
(switched on: 800 ms, switched off : 1 ms), fl uence: 12 J/
cm2, duty factor of 80%, area: 1 cm2. Laser irradiation 
was applied in non-contact mode on the site in the 
mouth where burning symptoms were present. Th e dis-
tance between the probe and the irradiated area was 
kept constant at approximately 5 mm throughout the 
treatment protocol. Th e slow circulation movements 
were performed during the treatment. Th e LLLT was 
repeated every day except for weekend for 14 days (10 
sessions). Every session lasted for 5 minutes.
Each participant fi lled out the VAS and OHIP-
CRO 14 before and after either therapy11.
Statistical analysis
Normality of distribution was assessed by Kol-
mogorov-Smirnov test. Due to normal distribution of 
the variables, parametric statistics was used. Data were 
expressed as mean ± standard deviation. Diff erences 
between the groups were assessed by Student’s t-test. 
Diff erence before and after treatment in each group 
was assessed by paired samples t test. Th e values of p 
lower than 0.05 (p<0.05) were considered statistically 
signifi cant.
Results
Two participants did not fi ll out the VAS scale. 
Th ere were no signifi cant diff erences in either study or 
control group before and after LLLT (switched on and 
off ) regarding the quality of life (OHIP CRO 14 
scores) (Table 1).
Signifi cant diff erence before and after laser on and 
off  regarding VAS scores (decrease of pain symptoms) 
Table 1. OHIP scores before and after therapy protocol 
in study (‘laser on’) group and control (‘laser off ’) group
Mean SD p
OHIP before and after 
in ‘laser on’ group
2.727 8.631 0.153
OHIP before and after 
in ‘laser off ’ group
1.273 5.642 0.302
OHIP = Oral Health Impact Profi le questionnaire; SD = standard 
deviation; p = statistical signifi cance set at 0.05
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was found in both study group (‘laser on’) and control 
group (‘laser off ’) (Table 2).
Discussion
Th ere are only three studies published so far on the 
placebo eff ect of LLLT (i.e. when LLLT was switched 
off )7-9. Arbabi-Kalati et al.7 compared LLLT on and 
LLLT off  (sham) in 20 patients with BMS. Th e LLLT 
was performed with 630 nm diode laser (power 30 
mW) for 10 seconds twice a week. After four weeks of 
treatment, LLLT reduced burning sensation and im-
proved the quality of life. Furthermore, Spanemberg et 
al.9 also report decreased symptoms and improved 
quality of life in 78 BMS patients after eight weeks of 
LLLT at fl uence of 176 J/cm2 and 72 J/cm2. In the 
present single-blinded study, LLLT (12 J/cm2) de-
creased the burning mouth symptoms after 10 ses-
sions. However, there was no improvement in the 
quality of life. Another interesting fi nding of this study 
was a decrease of symptoms in the placebo group 
where LLLT was off . It may be that placebo played an 
important role in alleviating burning symptoms in the 
patients included in the study.
In the study by Arduino et al.12, 18 patients with 
BMS were treated with LLLT using continuous mode 
of 980-nm AlGaAs laser (output power: 300 mW, fl u-
ence: 10 J/cm2) and the ‘spot technique’, with an aver-
age power density of about 1  W/cm2 and the laser 
probe held perpendicularly at a distance of about 
2 mm from the mucosa. Th e treatment lasted for fi ve 
weeks with two laser irradiation sessions weekly. Fi-
nally, they concluded that LLLT was superior to clon-
azepam regarding improvement in pain perception at 
8 weeks, based on the VAS, McGill Pain Question-
naire, present pain intensity and OHIP-49. Th e pa-
tients experienced reduction of burning symptoms 
from the end of fi rst applications. However, LLLT did 
not infl uence anxiety and depression. Kato et al.13 ir-
radiated 11 patients with BMS once a week for three 
consecutive weeks with an infrared laser (790 nm, fl u-
ence: 6 J/cm2, output power: 120 mW). Th e probe was 
kept in contact with the tissue. Burning symptoms 
were signifi cantly lower after the end of LLLT. Pa-
tients reported an 80.4% reduction in the intensity of 
symptoms after LLLT. Dos Santos et al.14 investigated 
the eff ect of one weekly session of LLLT (660 nm, 
power: 40 mW, fl uence: 20 J/cm2) for 10 weeks in ten 
patients with oral burning. All patients reported im-
provement in all sessions, with reduction in VAS scores 
by up to 58% after the 10th session. Yang and Huang15 
treated 17 BMS patients with an 800-nm wavelength 
diode laser (1.5 W/cm2) between one and seven times. 
Th e results showed the mean reduction in pain by 
47.6% (ranging from 9.3% to 91.8%). Th e burning 
sensation remained unchanged for up to 12 months.
Romeo et al.16 report on benefi cial eff ects of LLLT 
in 25 patients. All patients were irradiated with a dou-
ble diode laser (fl uence: 0.53 J/cm2) for 15 minutes 
twice a week for 4 weeks. Seventeen (68%) patients 
had relevant benefi ts while in 8 cases diff erences in 
burning were not relevant. Pezelj Ribaric et al.17 could 
not confi rm signifi cant diff erence in VAS after 4 weeks 
of LLLT, however, the salivary levels of tumor necrosis 
factor α and interleukin-6 decreased signifi cantly.
According to the above mentioned clinical studies, 
there still are diff erences in laser parameters and dura-
tion of LLLT among studies, thus direct comparison is 
not possible. Following the results of this study, it can-
not be explained why the quality of life was not im-
proved after LLLT, although VAS scores were im-
proved in both the treatment and placebo groups. 
Th erefore, more randomized single-blinded clinical 
studies comparing LLLT on and off  (placebo) are nec-
essary to clarify the role of LLLT in the treatment of 
patients with BMS.
In conclusion, both the switched on and switched 
off  LLLT decreased pain symptoms in patients with 
BMS, however, neither of the therapy protocols im-
proved the quality of life scores. 
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Sažetak
UČINKOVITOST LIJEČENJA NISKOENERGETSKIM LASEROM U SINDROMU PEKUĆIH USTA 
– PROBNO ISTRAŽIVANJE
M. Sikora, A. Včev, S. Siber, V. Vučićević Boras, Ž. Rotim i M. Matijević
Cilj ovoga istraživanja je bio usporediti učinkovitost niskoenergetskog lasera koji je bio uključen i isključen u bolesnika 
sa sindromom pekućih usta (SPU). SPU je stanje koje iscrpljuje bolesnike, zahtjevno je za liječenje, a očituje se simptomima 
žarenja u usnoj šupljini. Usprkos brojnim istraživanjima do sada su se kognitivna bihejvioralna terapija i klonazepam jedini 
pokazali kao uspješan način liječenja SPU u randomiziranim kontroliranim istraživanjima. Četrdeset i četiri bolesnika s SPU 
su podijeljeni u skupinu koja je liječena upaljenim laserom i u skupinu koja je liječena ugašenim laserom. Liječenje laserom 
je provedeno uz pomoć lasera GaAlAs (830 nm) koji je korišten u nekontaktnom načinu rada na mjestu gdje su u ustima bili 
prisutni simptomi žarenja, a sudionici su dobili po deset terapija (deset dana). Svaki sudionik je prije i poslije istraživanja 
odredio stupanj boli na vizualnoj analognoj ljestvici (VAS) te ispunio upitnik o utjecaju oralnog zdravlja na kvalitetu života 
(OHIP-CRO 14). Nije bilo značajnih razlika između skupina prije i nakon liječenja laserom (upaljen i ugašen) u utjecaju 
oralnog zdravlja na kvalitetu života (OHIP CRO 14) (p>0,05). Utvrđeno je značajno smanjenje simptoma boli (VAS) u 
objema skupinama liječenim laserom (upaljen i ugašen) (p<0,05). Upaljen i ugašen laser je doveo do smanjenja simptoma boli 
u bolesnika s SPU, doduše, niti jedan način liječenja laserom (upaljen ili ugašen) nije doveo do poboljšanja rezultata utjecaja 
oralnog zdravlja na kvalitetu života.
Ključne riječi: niskorazinska laserska terapija; sindrom pekućih usta; kognitivna terapija; kvaliteta života
